Psychedelic-Assisted Therapy: What the Clinical Trials Are Showing

Therapy & Treatment · 3 · March 22, 2026

In 2024, the FDA granted breakthrough therapy designation to psilocybin for treatment-resistant depression and MDMA for PTSD. These aren't fringe ideas anymore — they're backed by Phase 2 and Phase 3 clinical trials published in the New England Journal of Medicine, The Lancet, and Nature Medicine. The results are unlike anything in conventional psychiatry.

Psilocybin for Depression

A 2022 NEJM trial compared psilocybin (two sessions, 25mg each, with therapy support) to escitalopram (daily SSRI for 6 weeks) in 59 patients with moderate-severe depression. Both groups improved, but psilocybin showed faster onset (within 1 week vs 3-4 weeks) and greater improvement on secondary measures including quality of life. The COMPASS Pathways Phase 2b trial (233 patients with treatment-resistant depression) found that a single 25mg psilocybin dose produced clinically significant improvement in 37% of patients at 3 weeks, compared to 8% on placebo. These are patients who had failed two or more antidepressant medications.

MDMA for PTSD

Three Phase 3 trials (MAPS-sponsored) tested MDMA-assisted therapy for severe PTSD. In the first trial (2021, Nature Medicine), 67% of MDMA participants no longer met PTSD diagnostic criteria after three sessions, compared to 32% in the placebo group. The effect held at 12-month follow-up. MDMA doesn't cure PTSD alone — it's administered during 8-hour therapy sessions where the drug's effects (reduced fear, increased trust, emotional openness) allow patients to process traumatic memories they couldn't access otherwise.

Ketamine: Already Available

Unlike psilocybin and MDMA (still in trials), ketamine is already legally prescribed. Esketamine (Spravato) is FDA-approved for treatment-resistant depression as a nasal spray administered in a clinic. IV ketamine infusions are available off-label at ketamine clinics ($400-$800 per session, typically 6 sessions). A 2023 meta-analysis in the American Journal of Psychiatry found ketamine produced rapid antidepressant effects within 24 hours — compared to weeks for SSRIs — with response rates of 60-70% in treatment-resistant patients. The effects typically last 1-2 weeks per infusion.

Cautions and Context

These are not party drugs being repurposed casually. Clinical psychedelic therapy involves careful screening (excluding patients with psychotic disorders, severe cardiac conditions, and certain medications), trained therapists, controlled doses, and integration sessions afterward. Self-administering psychedelics without clinical support does not replicate trial conditions and carries real risks including adverse psychological reactions. The FDA approval process is rigorous precisely because the context — trained guides, therapeutic setting, integration — is part of the treatment itself.

Key Takeaways

- Psilocybin produced significant improvement in 37% of treatment-resistant depression patients — vs 8% on placebo

- 67% of MDMA-treated PTSD patients no longer met diagnostic criteria after 3 sessions

- Ketamine (esketamine) is already FDA-approved and works within 24 hours

- These treatments require clinical supervision — self-administration doesn't replicate trial conditions

Learn about emerging treatments at our medical knowledge graph.